New nipocalimab data and real-world research at aan 2025 highlight positive phase 3 results and commitment to people living with generalized myasthenia gravis (gmg)

Oral presentation features new data from the 24-week pivotal vivacity-mg3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed qmga score in antibody positive adult patients: anti-achr+, anti-musk+, anti-lrp4+ nipocalimab data demonstrate longer-term sustained disease control as measured by mg-adlb and qmg scores from the ongoing open-label extension (ole) of the vivacity-mg3 study johnson & johnson filed a biologics license application (bla) for nipocalimab in august 2024 and was granted u.s. fda priority review for the treatment of gmg  real-world studies highlight the unmet need of patients living with gmg, including those who are pregnant or receiving steroids spring house, pa. , march 26, 2025 /prnewswire/ -- johnson & johnson (nyse: jnj) announced today that 12 abstracts, including two oral presentations, highlighting the company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gmg), will be presented at the 2025 american academy of neurology (aan) annual meeting from april 5 – 9 in san diego, california.
AAN Ratings Summary
AAN Quant Ranking